Mondego Bio
Latest round
- Series A
Last raised
- Sep 2025
Total raised
- Undisclosed
Investors
- 3
About Mondego Bio
Founded in Cantanhede, Portugal, Mondego Bio is dedicated to developing therapies targeting the JAK-STAT signaling pathway to improve cancer immunotherapy.Mondego Bio specializes in the development of Protein Tyrosine Phosphatase Non-Receptor Type 2 (PTPN2) inhibitors, targeting the JAK-STAT signaling pathway.). The product is currently in preclinical stages, with promising data reported at international scientific workshops and conferences. Mondego Bio primarily serves the oncology field, targeting healthcare providers and pharmaceutical companies looking to advance cancer immunotherapy solutions.Mondego Bio's revenue model is structured around partnerships and collaborations with industry leaders and research institutions focused on cancer immunotherapy. The company engages in direct B2B transactions, collaborating with pharmaceutical firms that are interested in licensing or co-developing its PTPN2 inhibitor candidates. The pricing structure, while not publicly disclosed, is expected to align with industry standards for innovative biopharmaceuticals, reflecting the complexity and potential of their flagship product, ZE00-0388, in the competitive oncology market. Mondego Bio is also planning to expand its market presence into additional regions, specifically targeting North America and parts of Europe, by 2026, to enhance its engagement with pharmaceutical partners and research institutions.
Who invested in Mondego Bio
3 investors across 1 round
See all investors in Mondego Bio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Sep 18, 2025
Amount
Undisclosed
Investors
Questions about Mondego Bio
Who invested in Mondego Bio?
Mondego Bio has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Mondego Bio raised?
Mondego Bio has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Mondego Bio last raise money?
Mondego Bio's most recent round on record is a Series A, in Sep 2025.
What does Mondego Bio do?
Founded in Cantanhede, Portugal, Mondego Bio is dedicated to developing therapies targeting the JAK-STAT signaling pathway to improve cancer immunotherapy.
Where is Mondego Bio headquartered?
Mondego Bio is headquartered in Cantanhede, Portugal.
Which VCs invest in companies like Mondego Bio?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Mondego Bio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Mondego Bio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.